First BGE-102 MAD cohort completed in obese individuals with elevated hsCRP receiving 120 mg QD; demonstrated rapid and profound reduction in inflammatory markers BGE-102 achieved 86% reduction in ...
BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapies Growing preclinical and ...
Pictured is Lee Lennard, PE, F. SAME, current president and CEO of BGE, with Randy Randermann, PE, (Right) who will serve as the Company's next president and CEO, effective January 2026. As the firm ...
BioAge Labs, Inc. (NASDAQ:BIOA), a clinical-stage biotech innovator, announced today the completion of IND-enabling studies for its groundbreaking oral NLRP3 inhibitor, BGE-102, targeting obesity. The ...
BGE is proud to announce the election of four new board members: Michael Fitzgerald, Michael Franklin, Roman Grijalva, and Chris Kuykendall. These individuals have demonstrated exceptional leadership, ...
HOUSTON--(BUSINESS WIRE)--BGE, Inc. announced today that industry leader Jenny Urcan, PE, has joined the firm as Director of Land/Site Development to launch the firm’s presence in Jacksonville, ...
Crowning itself a city of the future, Charlotte is a bright spot for BGE’s community focus and growth as a leading engineering consulting firm. An emerging city of the future, Charlotte offers a ...
RICHMOND, Calif.--(BUSINESS WIRE)--BioAge Labs, Inc. (“BioAge”), a clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results